Randomized controlled study to evaluate the efficacy of adalimumab in patients with different forms of refractory uveitis
Purpose: TNF alpha inhibitors have revolutionized the care of vision-threatening uveitis. This study evaluated the efficacy of adalimumab (ADA) for the treatment of refractory noninfectious uveitis.Design: Randomized, prospective, controlled, two-center clinical trialMethods: Patients with active uv...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2018
|
| In: |
Ocular immunology and inflammation
Year: 2017, Jahrgang: 26, Heft: 7, Pages: 1015-1022 |
| ISSN: | 1744-5078 |
| DOI: | 10.1080/09273948.2017.1411518 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1080/09273948.2017.1411518 Verlag, Volltext: https://doi.org/10.1080/09273948.2017.1411518 
|
| Verfasserangaben: | Friederike Mackensen, MD, Carsten Heinz, MD, Eva Jakob, MD, Viviane Grewing, MD, Hanns-Martin Lorenz, MD, Arnd Heiligenhaus, MD, Regina Max, MD, and Matthias D. Becker, MD, PhD |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 157805088X | ||
| 003 | DE-627 | ||
| 005 | 20220814203140.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180730r20182017xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/09273948.2017.1411518 |2 doi | |
| 035 | |a (DE-627)157805088X | ||
| 035 | |a (DE-576)50805088X | ||
| 035 | |a (DE-599)BSZ50805088X | ||
| 035 | |a (OCoLC)1341014678 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mackensen, Friederike |d 1974-2016 |e VerfasserIn |0 (DE-588)123739594 |0 (DE-627)706412761 |0 (DE-576)29385386X |4 aut | |
| 245 | 1 | 0 | |a Randomized controlled study to evaluate the efficacy of adalimumab in patients with different forms of refractory uveitis |c Friederike Mackensen, MD, Carsten Heinz, MD, Eva Jakob, MD, Viviane Grewing, MD, Hanns-Martin Lorenz, MD, Arnd Heiligenhaus, MD, Regina Max, MD, and Matthias D. Becker, MD, PhD |
| 264 | 1 | |c 2018 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 29 Dec 2017 | ||
| 500 | |a Gesehen am 05.08.2019 | ||
| 520 | |a Purpose: TNF alpha inhibitors have revolutionized the care of vision-threatening uveitis. This study evaluated the efficacy of adalimumab (ADA) for the treatment of refractory noninfectious uveitis.Design: Randomized, prospective, controlled, two-center clinical trialMethods: Patients with active uveitis despite combined oral low-dose prednisolone and immunosuppression were randomized for additional ADA with corticosteroids in a fixed tapering regime, or corticosteroids only. Primary outcome measure at three months was improved best-corrected visual acuity (BCVA; >2 lines). In case of treatment failure, switch to the other arm was possible.Results: Twenty-five patients (10 ADA, 15 controls) were included. BCVA increased with ADA by > 2 lines in 6/10 patients (60%; mean increase of 0.23 logMAR), but in only 2/15 from controls (13%, mean increase of 0.04 logMAR, Fisher´s exact test p = 0.00221).Conclusions: The results show superiority of ADA over controls in severe ocular inflammation including anterior uveitis. | ||
| 534 | |c 2017 | ||
| 650 | 4 | |a Adalimumab | |
| 650 | 4 | |a anterior uveitis | |
| 650 | 4 | |a biological therapy | |
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a uveitis | |
| 700 | 1 | |a Jakob, Eva |d 1982- |e VerfasserIn |0 (DE-588)136112323 |0 (DE-627)694090476 |0 (DE-576)284683191 |4 aut | |
| 700 | 1 | |a Grewing, Viviane |d 1991- |e VerfasserIn |0 (DE-588)1147776334 |0 (DE-627)1007177233 |0 (DE-576)49602941X |4 aut | |
| 700 | 1 | |a Lorenz, Hanns-Martin |d 1962- |e VerfasserIn |0 (DE-588)112253865 |0 (DE-627)627277845 |0 (DE-576)167601369 |4 aut | |
| 700 | 1 | |a Max, Regina |e VerfasserIn |0 (DE-588)1050991001 |0 (DE-627)785478418 |0 (DE-576)176590609 |4 aut | |
| 700 | 1 | |a Becker, Matthias D. |e VerfasserIn |0 (DE-588)135571855 |0 (DE-627)56707255X |0 (DE-576)300521871 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ocular immunology and inflammation |d Abingdon : Taylor & Francis Group, 1993 |g 26(2018), 7, Seite 1015-1022 |h Online-Ressource |w (DE-627)300595034 |w (DE-600)1483057-7 |w (DE-576)273877720 |x 1744-5078 |7 nnas |a Randomized controlled study to evaluate the efficacy of adalimumab in patients with different forms of refractory uveitis |
| 773 | 1 | 8 | |g volume:26 |g year:2018 |g number:7 |g pages:1015-1022 |g extent:8 |a Randomized controlled study to evaluate the efficacy of adalimumab in patients with different forms of refractory uveitis |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/09273948.2017.1411518 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1080/09273948.2017.1411518 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180730 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 135571855 |a Becker, Matthias D. |m 135571855:Becker, Matthias D. |d 50000 |e 50000PB135571855 |k 0/50000/ |p 8 |y j | ||
| 998 | |g 1050991001 |a Max, Regina |m 1050991001:Max, Regina |d 910000 |d 910100 |e 910000PM1050991001 |e 910100PM1050991001 |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 998 | |g 112253865 |a Lorenz, Hanns-Martin |m 112253865:Lorenz, Hanns-Martin |d 910000 |d 910100 |e 910000PL112253865 |e 910100PL112253865 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 998 | |g 1147776334 |a Grewing, Viviane |m 1147776334:Grewing, Viviane |d 910000 |d 910900 |e 910000PG1147776334 |e 910900PG1147776334 |k 0/910000/ |k 1/910000/910900/ |p 4 | ||
| 998 | |g 136112323 |a Jakob, Eva |m 136112323:Jakob, Eva |d 910000 |d 910900 |e 910000PJ136112323 |e 910900PJ136112323 |k 0/910000/ |k 1/910000/910900/ |p 3 | ||
| 998 | |g 123739594 |a Mackensen, Friederike |m 123739594:Mackensen, Friederike |d 50000 |e 50000PM123739594 |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN157805088X |e 3019718139 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"recId":"300595034","note":["Gesehen am 08.09.15"],"pubHistory":["1.1993 -"],"part":{"year":"2018","pages":"1015-1022","extent":"8","volume":"26","text":"26(2018), 7, Seite 1015-1022","issue":"7"},"language":["eng"],"title":[{"title":"Ocular immunology and inflammation","title_sort":"Ocular immunology and inflammation"}],"id":{"zdb":["1483057-7"],"issn":["1744-5078"],"eki":["300595034"]},"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"1993-","publisher":"Taylor & Francis Group ; Informa Healthcare","publisherPlace":"Abingdon ; New York, NY [u.a.]","dateIssuedKey":"1993"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Randomized controlled study to evaluate the efficacy of adalimumab in patients with different forms of refractory uveitisOcular immunology and inflammation"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"2018"}],"id":{"eki":["157805088X"],"doi":["10.1080/09273948.2017.1411518"]},"physDesc":[{"extent":"8 S."}],"person":[{"display":"Mackensen, Friederike","given":"Friederike","family":"Mackensen","role":"aut","roleDisplay":"VerfasserIn"},{"display":"Jakob, Eva","family":"Jakob","given":"Eva","role":"aut","roleDisplay":"VerfasserIn"},{"display":"Grewing, Viviane","given":"Viviane","family":"Grewing","role":"aut","roleDisplay":"VerfasserIn"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Lorenz, Hanns-Martin","given":"Hanns-Martin","family":"Lorenz"},{"roleDisplay":"VerfasserIn","role":"aut","display":"Max, Regina","given":"Regina","family":"Max"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Becker, Matthias D.","family":"Becker","given":"Matthias D."}],"name":{"displayForm":["Friederike Mackensen, MD, Carsten Heinz, MD, Eva Jakob, MD, Viviane Grewing, MD, Hanns-Martin Lorenz, MD, Arnd Heiligenhaus, MD, Regina Max, MD, and Matthias D. Becker, MD, PhD"]},"title":[{"title":"Randomized controlled study to evaluate the efficacy of adalimumab in patients with different forms of refractory uveitis","title_sort":"Randomized controlled study to evaluate the efficacy of adalimumab in patients with different forms of refractory uveitis"}],"language":["eng"],"note":["Published online: 29 Dec 2017","Gesehen am 05.08.2019"],"recId":"157805088X"} | ||
| SRT | |a MACKENSENFRANDOMIZED2018 | ||